BP005249: Human LILRB1/CD85j/ILT2 Domain1&2 Protein with the C-His Tag
Source: The recombinant Human LILRB1/CD85j/ILT2 Domain1&2 Protein, (amino acids Gly24-Gly221) fused with a His tag at the C-terminus, was produced in HEK 293 cells.
Activity: Immobilized recombinant Human LILRB1 Domain1&2 protein with the C-His tag at 1 ug/ml (100 ul/Well) on the plate. Dose response curve for the recombinant Anti-LILRB1 Antibody protein with the C-hFc tag with the EC50 of 16.9 ng/ml determined by ELISA (QC Test). The affinity constant of 1.9 uM as determined in SPR assay (Biacore T200).
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.BP000186-CYT-020: Recombinant Human FGF 23
Source: E. coli-derived.
The biological activity was measured in a cell proliferation assay using NIH/3T3 mouse embryonic fibroblasts. The ED50 for this effect is typically 0.05-0.5 ug/ml in the presence of 5 ug/ml of Recombinant Mouse Klotho and 10 ug/ml of heparin.
Purity > 95%, by SDS-PAGE.BP000186-CYT-028: Recombinant Human FGF 23 C-Terminal
Source: E. coli-derived.
Purity: > 90.0% as determined by densitometric image analysis.
Applications: WB.BP000186-CYT-374: Recombinant Human FGF 23, His Tag
Source: E. coli-derived.
Treatment with hrFGF23 has been shown to induce FGFR mediated Erk phosphorylation, reduce plasma PTH levels in rats and to reduce blood phosphate levels (Ref 1).
Purity > 90%, by SDS-PAGE and RP-HPLC.